Aquestive Therapeutics: Funding, Investors & Team (Sep 2026)
Aquestive Therapeutics, Inc. is a pharmaceutical company that aims to improve the lives of patients by developing innovative medicines. They are focused on creating orally administered products that can deliver complex molecules, providing better alternatives to current invasive and inconvenient therapies. Currently, Aquestive has five products being sold in the U.S. market, with four licensed products and one proprietary product called Sympazan® for the treatment of seizures. They also collaborate with other pharmaceutical companies to bring new molecules to the market using their own technologies, such as PharmFilm®. Additionally, Aquestive has a strong capability in drug development and commercialization. The company's main focus is on developing products for the central nervous system diseases, with a late-stage pipeline, and they also have an earlier stage pipeline for severe allergic reactions like anaphylaxis.
Aquestive Therapeutics has raised $100M across 2 funding rounds on record, the most recent an undisclosed round of $55.0M announced in May 2026.
That round is above the $4.7M median round size for Health Care companies tracked on FundedIQ over the last two years.
Aquestive Therapeutics Company Profile and Key Stats
Latest funding round on record: May 2026.
Aquestive Therapeutics Funding Rounds
Aquestive Therapeutics raised $45.0M in an undisclosed round announced in Nov 2023.
2.5 years later, an undisclosed round of $55.0M was announced in May 2026.
Aquestive Therapeutics Founders and Leadership Team
Contact details for the Aquestive Therapeutics team: 1 of 2 have an email address on file, 1 has a LinkedIn profile.
Start 14-day free trial →Aquestive Therapeutics Funding Compared to Other Health Care Startups
Aquestive Therapeutics' latest round of $55.0M is above the median round in Health Care. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Aquestive Therapeutics in Health Care and Warren
Companies Similar to Aquestive Therapeutics
https://metriport.com
There are too many reasons why Healthcare is unaffordable in the U.S, but one of the largest is waste. Up to…
Serif Health provides healthcare price intelligence and contract management solution.
Switchboard Health provides virtual care solutions to payers, health systems, employers, and at-risk…
Astek Diagnostics has designed a system that helps doctors choose the right antibiotics for patients…
TECLens is developing a crosslinking technology that can effectively address vision problems in both healthy…
Healthcare Shares operates as a crowdfunding portal for the transformative medical innovations of the future.
Gradient Health collaborates with medical data providers worldwide to assemble diseases and conditions for AI…
Kalivir designs safe and potent oncolytic product candidates across multiple tumor types. Kalivir’s…
Happy Health is a mission-driven technology company committed to transforming mental health awareness through…
Leal Therapeutics creates new treatments for patients.
Teal Health is on a mission to empower women when it comes to their health – starting with at-home cervical…
Aquestive Therapeutics Funding FAQs
What does Aquestive Therapeutics do?
Aquestive Therapeutics, Inc. is a pharmaceutical company that aims to improve the lives of patients by developing innovative medicines. They are focused on creating orally administered products that can deliver complex molecules, providing better alternatives to current invasive and inconvenient therapies. Currently, Aquestive has five products being sold in the U.S. market, with four licensed products and one proprietary product called Sympazan® for the treatment of seizures. They also collaborate with other pharmaceutical companies to bring new molecules to the market using their own technologies, such as PharmFilm®. Additionally, Aquestive has a strong capability in drug development and commercialization. The company's main focus is on developing products for the central nervous system diseases, with a late-stage pipeline, and they also have an earlier stage pipeline for severe allergic reactions like anaphylaxis.
How much funding has Aquestive Therapeutics raised?
Aquestive Therapeutics has raised $100M across 2 rounds on record. The most recent is an undisclosed round of $55.0M announced in May 2026.
When did Aquestive Therapeutics last raise funding?
Aquestive Therapeutics' most recent funding round on record is an undisclosed round of $55.0M, announced in May 2026.
Who founded Aquestive Therapeutics?
FundedIQ lists Daniel Barber (Founder), Rajesh Kainthan (Founder) at Aquestive Therapeutics.
Where is Aquestive Therapeutics headquartered?
Aquestive Therapeutics is based in Warren, New Jersey, United States.
How many employees does Aquestive Therapeutics have?
Aquestive Therapeutics is in the 101-250 employee band.
How does Aquestive Therapeutics' funding compare to other Health Care startups?
Aquestive Therapeutics' latest round of $55.0M is above the $4.7M median round size for Health Care companies on FundedIQ across 3,653 tracked companies over the last two years.
About FundedIQ's Aquestive Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Aquestive Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.